| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 784 | 2022 |
| Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126, 2019 | 468 | 2019 |
| Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 417 | 2018 |
| Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ... Clinical Cancer Research 26 (13), 3239-3247, 2020 | 164 | 2020 |
| Immunotherapy in hepatocellular carcinoma: Primed to make a difference? JJ Harding, I El Dika, GK Abou‐Alfa Cancer 122 (3), 367-377, 2016 | 131 | 2016 |
| Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, D Niedzwiecki, J Posey, ... JAMA oncology 5 (11), 1582-1588, 2019 | 108 | 2019 |
| Immune checkpoint inhibitors for hepatocellular carcinoma I El Dika, DN Khalil, GK Abou‐Alfa Cancer 125 (19), 3312-3319, 2019 | 95 | 2019 |
| An open‐label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of … I El Dika, HY Lim, WP Yong, CC Lin, JH Yoon, M Modiano, B Freilich, ... The oncologist 24 (6), 747-e218, 2019 | 91 | 2019 |
| Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings H Maynard, ZK Stadler, MF Berger, DB Solit, M Ly, MA Lowery, ... Cancer 126 (9), 1995-2002, 2020 | 40 | 2020 |
| A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies JJ Harding, RK Do, IE Dika, E Hollywood, K Uhlitskykh, E Valentino, ... Cancer chemotherapy and pharmacology 82, 429-440, 2018 | 39 | 2018 |
| Treatment options after sorafenib failure in patients with hepatocellular carcinoma I El Dika, GK Abou-Alfa Clinical and Molecular Hepatology 23 (4), 273, 2017 | 35 | 2017 |
| Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers MA Lowery, M Bradley, JF Chou, M Capanu, S Gerst, JJ Harding, IE Dika, ... Clinical Cancer Research 25 (3), 937-945, 2019 | 26 | 2019 |
| Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. A Cercek, MA Lumish, JC Sinopoli, JA Weiss, J Shia, ZK Stadler, ... Journal of Clinical Oncology 40 (17_suppl), LBA5-LBA5, 2022 | 23 | 2022 |
| Hyper-CVAD compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. A retrospective single-center analysis J El-Cheikh, I El Dika, R Massoud, M Charafeddine, R Mahfouz, ... Clinical Lymphoma Myeloma and Leukemia 17 (3), 179-185, 2017 | 23 | 2017 |
| Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with … MR Weiser, JF Chou, A Keshinro, WC Chapman, PS Bauer, MG Mutch, ... JAMA Network Open 4 (11), e2133457-e2133457, 2021 | 22 | 2021 |
| A multicenter randomized three‐arm Phase II study of (1) Everolimus,(2) Estrogen Deprivation Therapy (EDT) with Leuprolide+ Letrozole, and (3) Everolimus+ EDT in patients with … I El Dika, RJ Mayer, AP Venook, M Capanu, MP LaQuaglia, R Kobos, ... The oncologist 25 (11), 925-e1603, 2020 | 22 | 2020 |
| Hepatocellular carcinoma in patients with HIV I El Dika, JJ Harding, GK Abou-Alfa Current Opinion in HIV and AIDS 12 (1), 20-25, 2017 | 21 | 2017 |
| Liver and bile duct cancer GK Abou-Alfa, W Jarnagin, I El Dika, M D'Angelica, M Lowery, K Brown, ... Abeloff's clinical oncology, 1314-1341. e11, 2020 | 19 | 2020 |
| PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. MA Lumish, JL Cohen, ZK Stadler, JA Weiss, MF Lamendola-Essel, ... Journal of Clinical Oncology 40 (4_suppl), 16-16, 2022 | 17 | 2022 |
| Hepatocellular carcinoma, novel therapies on the horizon I El Dika, I Makki, GK Abou-Alfa Chinese clinical oncology 10 (1), 12, 2021 | 17 | 2021 |
